Insulet Corporation

Insulet (PODD) Stock May Trade At A Discount To Fair Value

Insulet has seen its share price fall hard over the past year, which puts the focus squarely on whether the current market value still lines up with the cash the business is expected to generate. With the stock under pressure, the key issue now is how its cash flows compare with the price investors are paying today. Over the past 12 months, Insulet shares have declined 57.2%. This puts a lot of weight on whether the business can support the present valuation through its future cash...

Yahoo Finance · 26/09/2026 · lire l'article ↗

Insulet (PODD) Reworked Its Debt, Is The Stock Still Cheap?

Insulet (PODD) recently reworked its financing by replacing $475 million of term loans with new debt at lower interest margins and expanding its revolving credit facility, a move that directly reshapes the balance sheet. Insulet’s refinancing lands after a tough stretch for the stock, with the share price down 52% year to date and the 1 year total shareholder return declining 58%. This points to fading momentum even before its recent index removal and conference appearances. Scan beyond...

Yahoo Finance · 25/09/2026 · lire l'article ↗

Insulet Targets Type 2 Retention as Omnipod 6 and Global Growth Gain Momentum

Insulet (NASDAQ:PODD) Chief Operating Officer Eric Benjamin said the company remains focused on expanding adoption of automated insulin delivery, or AID, systems across large and underpenetrated diabetes markets, while addressing elevated early attrition among certain Type 2 diabetes customers. Spe

Yahoo Finance · 25/09/2026 · lire l'article ↗

How Is Insulet's Stock Performance Compared to Other Medical Devices Stocks?

Insulet has notably underperformed the Medical Devices industry over the past year, but analysts are cautiously optimistic about the stock’s prospects.

Yahoo Finance · 24/09/2026 · lire l'article ↗

Insulet to Participate in Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum

ACTON, Mass., September 18, 2026--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum on Thursday, September 24, 2026, at 12:30 p.m. (Eastern Time).

Yahoo Finance · 18/09/2026 · lire l'article ↗

BCSM Exits Insulet Corporation (PODD), Maintains Watchlist Status

Baron Capital, an investment management company, released its second-quarter 2026 investor letter for its “Baron SMID Cap ETF”. You can download the letter here. Baron SMID Cap ETF® (BCSM) gained 15.62% (NAV) in the second quarter, underperforming the Russell 2500 Growth Index’s 24.02% return. The trend towards “AI winners” continued, focusing on companies related to chips, […]

Yahoo Finance · 17/09/2026 · lire l'article ↗